Market Research Logo

Bone Metastasis - Pipeline Review, H1 2018

Bone Metastasis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H1 2018, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 4, 1 and 18 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Bone Metastasis - Overview
Bone Metastasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Metastasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Metastasis - Companies Involved in Therapeutics Development
Ablynx NV
Amgen Inc
BiologicsMD Inc
CSPC Pharmaceutical Group Limited
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
Lupin Ltd
MabVax Therapeutics Holdings Inc
Mirati Therapeutics Inc
Oncobiologics Inc
Oncodrone BV
OPKO Health Inc
R Pharm
Serene LLC
Taiho Pharmaceutical Co Ltd
Terpenoid Therapeutics Inc
Bone Metastasis - Drug Profiles
ADM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-0141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1644 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKM-1740 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-3151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcifediol ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCC-3014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Osteomyelitis and Bone Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emibetuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LG-1980 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Connexin 43 for Breast Cancer and Bone Metastasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit JAG1 for Bone Metastasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OCD-155 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tin-117m-DTPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPH-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vicrostatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bone Metastasis - Dormant Projects
Bone Metastasis - Discontinued Products
Bone Metastasis - Product Development Milestones
Featured News & Press Releases
Jan 05, 2018: NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)
Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease
May 24, 2011: Daiichi Sankyo and AstraZeneca Announce a Co-Promotion Agreement in Japan for Denosumab, a Treatment of Bone Disorders stemming from Bone Metastasis
May 18, 2011: Amgen To Present XGEVA Data At ASCO Annual Meeting
Dec 10, 2010: Amgen Presents New XGEVA Breast Cancer Skeletal-Related Event Prevention Data At SABCS
Nov 18, 2010: Amgen Receives FDA Approval for XGEVA For Prevention Of Skeletal-Related Events In Patients With Bone Metastases From Solid Tumors
Nov 08, 2010: Amgen Announces Phase III Study Results Of Denosumab In Breast Cancer Patients With Bone Metastases
Nov 08, 2010: Published Results Show Denosumab Superior to Zometa in Delaying or Preventing Bone Complications in Patients with Bone Metastases From Advanced Breast Cancer
Oct 11, 2010: Amgen Reports Integrated Analysis Demonstrates That Denosumab Delays Onset Of Bone Complications Compared To Zometa
Jul 17, 2010: Amgen Receives FDA's Priority Review Designation For Denosumab BLA For Reduction Of Skeletal Related Events In Advanced Cancer Patients
May 14, 2010: Amgen Submits Denosumab BLA To FDA For Reduction Of Skeletal Related Events In Cancer Patients
Aug 03, 2009: Amgen Announces Positive Top-Line Results For Denosumab In Bone Metastases Patients Compared To Zometa
Jun 04, 2006: Amgen Announces Phase 2 Interim Data Of Denosumab In Advanced Cancer Patients With Bone Metastases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bone Metastasis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Bone Metastasis - Pipeline by Ablynx NV, H1 2018
Bone Metastasis - Pipeline by Amgen Inc, H1 2018
Bone Metastasis - Pipeline by BiologicsMD Inc, H1 2018
Bone Metastasis - Pipeline by CSPC Pharmaceutical Group Limited, H1 2018
Bone Metastasis - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018
Bone Metastasis - Pipeline by Eli Lilly and Co, H1 2018
Bone Metastasis - Pipeline by Lupin Ltd, H1 2018
Bone Metastasis - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018
Bone Metastasis - Pipeline by Mirati Therapeutics Inc, H1 2018
Bone Metastasis - Pipeline by Oncobiologics Inc, H1 2018
Bone Metastasis - Pipeline by Oncodrone BV, H1 2018
Bone Metastasis - Pipeline by OPKO Health Inc, H1 2018
Bone Metastasis - Pipeline by R Pharm, H1 2018
Bone Metastasis - Pipeline by Serene LLC, H1 2018
Bone Metastasis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018
Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H1 2018
Bone Metastasis - Dormant Projects, H1 2018
Bone Metastasis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Bone Metastasis - Dormant Projects, H1 2018 (Contd..2), H1 2018
Bone Metastasis - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Bone Metastasis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report